Graft-versus-Leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant

Journal of Immunology

Volumn 187, Issue 4, 2011, Pages 1653-1663

  Matte Martone, Catherine ^a   Venkatesan, Srividhya ^a   Tan, Hung Sheng ^a   Athanasiadis, Ioanna ^a   Chang, Julia ^a   Pavisic, Jovana ^a   Shlomchik, Warren D ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; NUCLEOPORIN 98; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR HOXA9; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BLAST CRISIS CHRONIC MYELOGENOUS LEUKEMIA; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENETIC TRANSDUCTION; GRAFT VERSUS LEUKEMIA EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE; WILD TYPE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BLAST CRISIS; GENES, ABL; GRAFT VS LEUKEMIA EFFECT; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 80051939651     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100311     Document Type: Article

References (50)

1. Van den Brink, M. R., and S. J. Burakoff. 2002. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat. Rev. Immunol. 2: 273-281. (Pubitemid 37323227)
2. Bleakley, M., and S. R. Riddell. 2004. Molecules and mechanisms of the graftversus- leukaemia effect. Nat. Rev. Cancer 4: 371-380. (Pubitemid 38579483)
3. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringdén, C. Rozman, B. Speck, et al. 1990. Graft-versusleukemia reactions after bone marrow transplantation. Blood 75: 555-562. (Pubitemid 20069191)
4. Kolb, H. J. 2008. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112: 4371-4383.
5. Childs, R., A. Chernoff, N. Contentin, E. Bahceci, D. Schrump, S. Leitman, E. J. Read, J. Tisdale, C. Dunbar, W. M. Linehan, et al. 2000. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N. Engl. J. Med. 343: 750-758.
6. Gahrton, G., H. Svensson, M. Cavo, J. Apperly, A. Bacigalupo, B. Björkstrand, J. Bladé, J. Cornelissen, A. De Laurenzi, T. Facon, et al European Group for Blood and Marrow Transplantation. 2001. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br. J. Haematol. 113: 209-216. (Pubitemid 32423325)
7. McGlave, P. 1990. Bone marrow transplants in chronic myelogenous leukemia: An overview of determinants of survival. Semin. Hematol. 27(3, Suppl. 4)23-30. (Pubitemid 20214491)
8. Porter, D. L., R. H. Collins, Jr., C. Hardy, N. A. Kernan, W. R. Drobyski, S. Giralt, M. E. Flowers, J. Casper, A. Leahey, P. Parker, et al. 2000. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95: 1214-1221. (Pubitemid 30099829)
9. Passweg, J. R., P. Tiberghien, J. Y. Cahn, M. R. Vowels, B. M. Camitta, R. P. Gale, R. H. Herzig, D. Hoelzer, M. M. Horowitz, N. Ifrah, et al. 1998. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 21: 153-158. (Pubitemid 28044008)
10. Lee, S. J., J. P. Klein, A. J. Barrett, O. Ringden, J. H. Antin, J. Y. Cahn, M. H. Carabasi, R. P. Gale, S. Giralt, G. A. Hale, et al. 2002. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 100: 406-414. (Pubitemid 34761100)
11. Daley, G. Q., R. A. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
12. Li, S., R. L. Ilaria, Jr., R. P. Million, G. Q. Daley, and R. A. Van Etten. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189: 1399-1412. (Pubitemid 29227526)
13. Matte, C. C., J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik. 2004. Graft-versus-leukemia in a retrovirally induced murine CML model: Mechanisms of T-cell killing. Blood 103: 4353-4361. (Pubitemid 38685384)
14. Zheng, H., C. Matte-Martone, H. Li, B. E. Anderson, S. Venketesan, H. Sheng Tan, D. Jain, J. McNiff, and W. D. Shlomchik. 2008. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111: 2476-2484. (Pubitemid 351451463)
15. Matte-Martone, C., J. Liu, D. Jain, J. McNiff, and W. D. Shlomchik. 2008. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 111: 3884-3892.
16. Dash, A. B., I. R. Williams, J. L. Kutok, M. H. Tomasson, E. Anastasiadou, K. Lindahl, S. Li, R. A. Van Etten, J. Borrow, D. Housman, et al. 2002. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc. Natl. Acad. Sci. USA 99: 7622-7627. (Pubitemid 34568741)
17. Borrow, J., A. M. Shearman, V. P. Stanton, Jr., R. Becher, T. Collins, A. J. Williams, I. Dubé, F. Katz, Y. L. Kwong, C. Morris, et al. 1996. The t(7;11) (p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat. Genet. 12: 159-167. (Pubitemid 26051296)
18. Yamamoto, K., Y. Nakamura, K. Saito, and S. Furusawa. 2000. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosomepositive chronic myelogenous leukaemia with t(7;11)(p15;p15). Br. J. Haematol. 109: 423-426. (Pubitemid 30350728)
19. Ahuja, H. G., L. Popplewell, L. Tcheurekdjian, and M. L. Slovak. 2001. NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia. Genes Chromosomes Cancer 30: 410-415. (Pubitemid 32216333)
20. Kroon, E., U. Thorsteinsdottir, N. Mayotte, T. Nakamura, and G. Sauvageau. 2001. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 20: 350-361. (Pubitemid 32126971)
21. Neering, S. J., T. Bushnell, S. Sozer, J. Ashton, R. M. Rossi, P. Y. Wang, D. R. Bell, D. Heinrich, A. Bottaro, and C. T. Jordan. 2007. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110: 2578-2585. (Pubitemid 47523181)
22. Diehl, G. E., H. H. Yue, K. Hsieh, A. A. Kuang, M. Ho, L. A. Morici, L. L. Lenz, D. Cado, L. W. Riley, and A. Winoto. 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877-889. (Pubitemid 39626676)
23. Shin, T., K. Yoshimura, T. Shin, E. B. Crafton, H. Tsuchiya, F. Housseau, H. Koseki, R. D. Schulick, L. Chen, and D. M. Pardoll. 2005. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J. Exp. Med. 201: 1531-1541. (Pubitemid 40720999)
24. Xu, H., J. A. Gonzalo, Y. St Pierre, I. R. Williams, T. S. Kupper, R. S. Cotran, T. A. Springer, and J. C. Gutierrez-Ramos. 1994. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J. Exp. Med. 180: 95-109. (Pubitemid 24181059)
25. Morita, S., T. Kojima, and T. Kitamura. 2000. Plat-E: An efficient and stable system for transient packaging of retroviruses. Gene Ther. 7: 1063-1066. (Pubitemid 30398356)
26. Matte, C. C., J. Liu, J. Cormier, B. E. Anderson, I. Athanasiadis, D. Jain, J. McNiff, and W. D. Shlomchik. 2004. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10: 987-992. (Pubitemid 39273741)
27. Andersson, G., B. M. Illigens, K. W. Johnson, D. Calderhead, C. LeGuern, G. Benichou, M. E. White-Scharf, and J. D. Down. 2003. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 101: 4305-4312. (Pubitemid 36857794)
28. Lebedeva, T., M. L. Dustin, and Y. Sykulev. 2005. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr. Opin. Immunol. 17: 251-258. (Pubitemid 40692659)
29. Shlomchik, W. D., M. S. Couzens, C. B. Tang, J. McNiff, M. E. Robert, J. Liu, M. J. Shlomchik, and S. G. Emerson. 1999. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285: 412-415. (Pubitemid 29343964)
30. Azuma, T., S. Yao, G. Zhu, A. S. Flies, S. J. Flies, and L. Chen. 2008. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-3643.
31. Zou, W., and L. Chen. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8: 467-477. (Pubitemid 351733418)
32. Bishop, M. R., E. P. Alyea, III, M. S. Cairo, J. H. Falkenburg, C. H. June, N. Kröger, R. F. Little, J. S. Miller, S. Z. Pavletic, D. Porter, et al. 2010. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 16: 563-564.
33. Teshima, T., R. Ordemann, P. Reddy, S. Gagin, C. Liu, K. R. Cooke, and J. L. Ferrara. 2002. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8: 575-581. (Pubitemid 34633434)
34. Quezada, S. A., T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, et al. 2010. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207: 637-650.
35. Bogen, B., B. Malissen, and W. Haas. 1986. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 16: 1373-1378. (Pubitemid 17206155)
36. Mumberg, D., P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96: 8633-8638. (Pubitemid 29354843)
37. Corthay, A., D. K. Skovseth, K. U. Lundin, E. Røsjø, H. Omholt, P. O. Hofgaard, G. Haraldsen, and B. Bogen. 2005. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22: 371-383. (Pubitemid 40387478)
38. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368. (Pubitemid 29028508)
39. Greenberg, P. D., M. A. Cheever, and A. Fefer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 154: 952-963. (Pubitemid 11060802)
40. Greenberg, P. D., D. E. Kern, and M. A. Cheever. 1985. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122-1134. (Pubitemid 15011329)
41. Voskoboinik, I., M. C. Thia, A. De Bono, K. Browne, E. Cretney, J. T. Jackson, P. K. Darcy, S. M. Jane, M. J. Smyth, and J. A. Trapani. 2004. The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene. J. Exp. Med. 200: 811-816. (Pubitemid 39299467)
42. Singer, G. G., and A. K. Abbas. 1994. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1: 365-371.
43. Dustin, M. L., and J. A. Cooper. 2000. The immunological synapse and the actin cytoskeleton: Molecular hardware for T cell signaling. Nat. Immunol. 1: 23-29.
44. Reddy, P., Y. Maeda, C. Liu, O. I. Krijanovski, R. Korngold, and J. L. Ferrara. 2005. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med. 11: 1244-1249. (Pubitemid 43093673)
45. Jones, S. C., G. F. Murphy, T. M. Friedman, and R. Korngold. 2003. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J. Clin. Invest. 112: 1880-1886. (Pubitemid 38063711)
46. Anderson, B. E., J. M. McNiff, D. Jain, B. R. Blazar, W. D. Shlomchik, and M. J. Shlomchik. 2005. Distinct roles for donor- and host-derived antigenpresenting cells and costimulatory molecules in murine chronic graft-versushost disease: Requirements depend on target organ. Blood 105: 2227-2234. (Pubitemid 40731817)
47. Liu, X., J. X. Gao, J. Wen, L. Yin, O. Li, T. Zuo, T. F. Gajewski, Y. X. Fu, P. Zheng, and Y. Liu. 2003. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med. 197: 1721-1730. (Pubitemid 36745347)
48. Loke, P., and J. P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100: 5336-5341. (Pubitemid 36542706)
49. Liang, S. C., Y. E. Latchman, J. E. Buhlmann, M. F. Tomczak, B. H. Horwitz, G. J. Freeman, and A. H. Sharpe. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33: 2706-2716. (Pubitemid 37337136)
50. Mumprecht, S., C. Schürch, J. Schwaller, M. Solenthaler, and A. F. Ochsenbein. 2009. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114: 1528-1536.